David Wambeke Buys 33,333 Shares of NeuroOne Medical Technologies (NASDAQ:NMTC) Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) insider David Wambeke purchased 33,333 shares of NeuroOne Medical Technologies stock in a transaction that occurred on Thursday, August 27th. The shares were bought at an average price of $2.01 per share, with a total value of $66,999.33. Following the completion of the transaction, the insider owned 199,999 shares of the company’s stock, valued at $401,997.99. This represents a 20.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NeuroOne Medical Technologies Price Performance

NASDAQ:NMTC opened at $1.62 on Tuesday. The firm has a market cap of $14.76 million, a price-to-earnings ratio of -1.71 and a beta of 0.65. The company has a 50 day moving average price of $2.08 and a 200-day moving average price of $3.43. NeuroOne Medical Technologies Corporation has a 1-year low of $1.42 and a 1-year high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.07). NeuroOne Medical Technologies had a negative net margin of 71.50% and a negative return on equity of 128.12%. The firm had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.17 million. On average, sell-side analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on NMTC. Maxim Group set a $5.00 target price on shares of NeuroOne Medical Technologies and gave the stock a “buy” rating in a research note on Friday, August 14th. LADENBURG THALM/SH SH lifted their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Weiss Ratings cut NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $7.33.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Bard Associates Inc. purchased a new stake in shares of NeuroOne Medical Technologies during the second quarter worth approximately $929,000. Essex Investment Management Co. LLC purchased a new stake in shares of NeuroOne Medical Technologies during the fourth quarter worth approximately $143,000. Virtu Financial LLC acquired a new position in NeuroOne Medical Technologies in the 3rd quarter valued at $88,000. Finally, Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies in the 1st quarter valued at $84,000. 16.07% of the stock is currently owned by institutional investors and hedge funds.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.